Home › Ovarian Epithelial Carcinoma › New Jersey › Clifton
Ovarian Epithelial Carcinoma clinical trials in Clifton, NJ
3 studies for Ovarian Epithelial Carcinoma are looking for participants at sites in and around Clifton (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
RecruitingPhase 2
- John Theurer Cancer Center /ID# 275756, Hackensack · 7 mi away
CT-95 in Advanced Cancers Associated With Mesothelin Expression
RecruitingPhase 1
- Context Investigational Site, Hackensack · 7 mi away
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
RecruitingPhase 1
- John Theurer Cancer Center Hackensack University Medical Center, Hackensack · 7 mi away
Ovarian Epithelial Carcinoma trials in other cities
- Durham, NC8 studies
- Boston, MA8 studies
- New York City, NY7 studies
- San Diego, CA7 studies
- Chicago, IL7 studies
- Baltimore, MD6 studies
- Philadelphia, PA6 studies
- Cleveland, OH6 studies
- Houston, TX6 studies
- Salt Lake City, UT5 studies
- Minneapolis, MN5 studies
- Portland, OR5 studies
Other studies in Clifton
- Non-Small Cell Lung Cancer24 studies
- Cancer (all types)15 studies
- Multiple Myeloma14 studies
- Metastatic Cancer12 studies
- Acute Myeloid Leukemia12 studies
- Breast Cancer12 studies
- Prostate Cancer12 studies
- Ovarian Cancer11 studies
- Lung Cancer10 studies
- Colorectal Cancer8 studies
- Head and Neck Squamous Cell Carcinoma8 studies
- Endometrial Cancer8 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.